Cargando…

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis

PURPOSE: Melanoma is the most aggressive form of skin cancer. Circulating tumor DNA (ctDNA) is a diagnostic and prognostic marker of melanoma. However, whether ctDNA mutations can independently predict survival remains controversial. This meta-analysis assessed the prognostic value of the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yang, Sun, Hongyan, Cong, Lele, Liu, Chenlu, Sun, Qian, Wu, Nan, Cong, Xianling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116156/ https://www.ncbi.nlm.nih.gov/pubmed/34035810 http://dx.doi.org/10.1155/2021/6660571

Ejemplares similares

Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis
por: Sun, Qian, et al.
Publicado: (2020)

The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis
por: Cong, Lele, et al.
Publicado: (2021)

Effect of Exogenous Hormones and Reproductive Factors in Female Melanoma: A Meta-Analysis [Response to Letter]
por: Sun, Qian, et al.
Publicado: (2022)

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
por: Wang, Fulong, et al.
Publicado: (2023)

Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis
por: Zhang, Chuan, et al.
Publicado: (2021)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
por: Sobczuk, Paweł, et al.
Publicado: (2022)

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis
por: Wu, Nan, et al.
Publicado: (2023)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

ctDNA as a prognostic biomarker in resectable CLM: Systematic review and meta-analysis
por: Wang, Da, et al.
Publicado: (2023)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma
por: Zhang, Chuan, et al.
Publicado: (2021)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis
por: Guo, Kaibo, et al.
Publicado: (2023)

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
por: Chen, Yao, et al.
Publicado: (2020)

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA
por: He, Na, et al.
Publicado: (2018)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
por: Tan, Xiangyu, et al.
Publicado: (2021)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data
por: Zhao, Songchen, et al.
Publicado: (2021)

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
por: Keller, Laura, et al.
Publicado: (2020)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

Real‐world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non‐small cell lung cancer
por: Long, Chaolian, et al.
Publicado: (2023)

Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
por: Domrazek, Kinga, et al.
Publicado: (2023)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
por: Marczynski, Gabriella Taques, et al.
Publicado: (2020)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vdu7nsr24lp7viirmd8proflep